Contact Us
Drug Search Results
More Filters [+]

Atrasentan

Alternative Names: atrasentan, CHK-01, CHK01, CHK 01
Latest Update: 2025-01-14
Latest Update Note: News Article

Product Description

Atrasentan is a highly selective ETAR antagonist with an approximate 1800:1 selectivity for ETAR to ETBR (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065231/)

Mechanisms of Action: ETa Antagonist,Mineralocorticoid Receptor Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - IgA Nephropathy *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chinook Therapeutics
Company Location: SEATTLE WA 98102
Company CEO: Eric Dobmeier
Additonal Commercial Interests: AbbVie

Clinical Description

Map of Global Clinical Trials for Atrasentan

Countries in Clinic: Argentina, Australia, Brazil, Canada, China, Colombia, Czech Republic, France, Germany, Hong Kong, India, Italy, Japan, Korea, Malaysia, New Zealand, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Glomerulonephritis|IgA Nephropathy|Kidney Diseases

Phase 2: Diabetic Nephropathy|Glomerulosclerosis, Focal Segmental|Glomerulosclerosis, Nodular|Nephritis, Hereditary

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CHK0101

P3

Unknown Status

IgA Nephropathy

2027-06-30

ALIGN

P3

Active, not recruiting

Glomerulonephritis|Kidney Diseases|IgA Nephropathy

2026-12-18

CHK01-03

P2

Unknown Status

IgA Nephropathy

2026-05-25

ASSIST

P2

Recruiting

Kidney Diseases|Glomerulonephritis|IgA Nephropathy

2025-10-22

Recent News Events

Date

Type

Title

01/14/2025

News Article

 CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

08/06/2024

News Article

 Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

04/30/2024

News Article

 EU Nephrologists Foresee Travere/CSL Vifor's FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy

04/15/2024

News Article

 New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

12/01/2023

PubMed

 Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.

12/01/2023

PubMed

 Post hoc analysis of the SONAR trial: potential analgesic effects of atrasentan?

05/02/2023

PubMed

 Endothelin Receptor Blocker Reverses Breast Cancer-Induced Cardiac Remodeling.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions